These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37052803)

  • 21. Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials.
    Bialer M; Perucca E
    Epilepsia; 2020 Jun; 61(6):1082-1089. PubMed ID: 32452568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis.
    Lattanzi S; Brigo F; Trinka E; Zaccara G; Cagnetti C; Del Giovane C; Silvestrini M
    Drugs; 2018 Nov; 78(17):1791-1804. PubMed ID: 30390221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
    Talwar A; Estes E; Aparasu R; Reddy DS
    Exp Neurol; 2023 Jan; 359():114238. PubMed ID: 36206805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
    Lattanzi S; Trinka E; Striano P; Rocchi C; Salvemini S; Silvestrini M; Brigo F
    CNS Drugs; 2021 Mar; 35(3):265-281. PubMed ID: 33754312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome: A Randomized Clinical Trial.
    Knupp KG; Scheffer IE; Ceulemans B; Sullivan JE; Nickels KC; Lagae L; Guerrini R; Zuberi SM; Nabbout R; Riney K; Shore S; Agarwal A; Lock M; Farfel GM; Galer BS; Gammaitoni AR; Davis R; Gil-Nagel A
    JAMA Neurol; 2022 Jun; 79(6):554-564. PubMed ID: 35499850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of antiseizure medication for Lennox-Gastaut syndrome: a systematic review and network meta-analysis.
    Zhang L; Wang J; Wang C
    Dev Med Child Neurol; 2022 Mar; 64(3):305-313. PubMed ID: 34590711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
    Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R
    Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel seizure outcomes in patients with Lennox-Gastaut syndrome: Post hoc analysis of seizure-free days in rufinamide Study 303.
    Auvin S; Williams B; McMurray R; Kumar D; Perdomo C; Malhotra M
    Epilepsia Open; 2019 Jun; 4(2):275-280. PubMed ID: 31168494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years.
    Conry JA; Ng YT; Kernitsky L; Mitchell WG; Veidemanis R; Drummond R; Isojarvi J; Lee D; Paolicchi JM;
    Epilepsia; 2014 Apr; 55(4):558-67. PubMed ID: 24580023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cannabidiol efficacy and clobazam status: A systematic review and meta-analysis.
    Lattanzi S; Trinka E; Striano P; Zaccara G; Del Giovane C; Nardone R; Silvestrini M; Brigo F
    Epilepsia; 2020 Jun; 61(6):1090-1098. PubMed ID: 32452532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.
    Chen JW; Borgelt LM; Blackmer AB
    Ann Pharmacother; 2019 Jun; 53(6):603-611. PubMed ID: 30616356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy and safety of cannabidiol (CBD) in children with treatment-resistant epilepsy: Results from a state-based expanded access program.
    Park YD; Linder DF; Pope J; Flamini JR; Moretz K; Diamond MP; Long SA
    Epilepsy Behav; 2020 Nov; 112():107474. PubMed ID: 33181893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of seizure frequency on quality of life in patients with Lennox-Gastaut syndrome or Dravet syndrome.
    Auvin S; Damera V; Martin M; Holland R; Simontacchi K; Saich A
    Epilepsy Behav; 2021 Oct; 123():108239. PubMed ID: 34375802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy.
    Franco V; Perucca E
    Drugs; 2019 Sep; 79(13):1435-1454. PubMed ID: 31372958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy.
    Villanueva V; García-Ron A; Smeyers P; Arias E; Soto V; García-Peñas JJ; González-Alguacil E; Sayas D; Serrano-Castro P; Garces M; Hampel K; Tomás M; Lara J; de Toledo M; Barceló I; Aledo-Serrano A; Gil-Nagel A; Iacampo L; Falip M; Saiz-Diaz RA; Gómez-Ibañez A; Sopelana D; Sanchez-Larsen A; López-González FJ
    Epilepsy Behav; 2022 Dec; 137(Pt A):108958. PubMed ID: 36327646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study.
    Knupp KG; Scheffer IE; Ceulemans B; Sullivan J; Nickels KC; Lagae L; Guerrini R; Zuberi SM; Nabbout R; Riney K; Agarwal A; Lock M; Dai D; Farfel GM; Galer BS; Gammaitoni AR; Polega S; Davis R; Gil-Nagel A
    Epilepsia; 2023 Jan; 64(1):139-151. PubMed ID: 36196777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials.
    Chung S; Ben-Menachem E; Sperling MR; Rosenfeld W; Fountain NB; Benbadis S; Hebert D; Isojärvi J; Doty P
    CNS Drugs; 2010 Dec; 24(12):1041-54. PubMed ID: 21090838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.
    Wechsler RT; Burdette DE; Gidal BE; Hyslop A; McGoldrick PE; Thiele EA; Valeriano J
    Epilepsia Open; 2024 Oct; 9(5):1632-1642. PubMed ID: 39007525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Highly purified cannabidiol improves stability and postural tone in adult patients with Lennox-Gastaut syndrome: A case series.
    Calvello C; Fernandes M; Lupo C; Placidi F; Izzi F; Bianco C; Celeste MG; Mercuri NB; Liguori C
    Epileptic Disord; 2023 Feb; 25(1):74-79. PubMed ID: 36946334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current and emerging pharmacotherapy for the treatment of Lennox-Gastaut syndrome.
    Besag FMC; Vasey MJ; Chin RFM
    Expert Opin Pharmacother; 2023; 24(11):1249-1268. PubMed ID: 37212330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.